###begin article-title 0
###xml 107 112 <span type="species:ncbi:9606">human</span>
Differential regulation of CCL-11/eotaxin-1 and CXCL-8/IL-8 by Gram-positive and Gram-negative bacteria in human airway smooth muscle cells
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Bacterial infections are a cause of exacerbation of airway disease. Airway smooth muscle cells (ASMC) are a source of inflammatory cytokines/chemokines that may propagate local airway inflammatory responses. We hypothesize that bacteria and bacterial products could induce cytokine/chemokine release from ASMC.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human ASMC were grown in culture and treated with whole bacteria or pathogen associated molecular patterns (PAMPs) for 24 or 48 h. The release of eotaxin-1, CXCL-8 or GMCSF was measured by ELISA.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 14 22 14 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 39 49 39 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 117 118 114 115 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 169 177 166 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 267 277 261 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 339 347 330 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 363 372 354 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 14 21 <span type="species:ncbi:562">E. coli</span>
###xml 39 48 <span type="species:ncbi:1280">S. aureus</span>
###xml 169 176 <span type="species:ncbi:562">E. coli</span>
###xml 267 276 <span type="species:ncbi:1280">S. aureus</span>
###xml 339 346 <span type="species:ncbi:562">E. coli</span>
###xml 363 372 <span type="species:ncbi:1280">S. aureus</span>
Gram-negative E. coli or Gram-positive S. aureus increased the release of CXCL-8, as did IL-1beta, LPS, FSL-1 and Pam3CSK4, whereas FK565, MODLys18 or Poly I:C did not. E. coli inhibited eotaxin-1 release under control conditions and after stimulation with IL-1beta. S. aureus tended to inhibit eotaxin-1 release stimulated with IL-1beta. E. coli or LPS, but not S. aureus, induced the release of GMCSF.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 167 174 167 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 184 194 184 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 49 54 <span type="species:ncbi:9606">human</span>
###xml 154 159 <span type="species:ncbi:9606">human</span>
###xml 167 174 <span type="species:ncbi:562">E. coli</span>
###xml 184 193 <span type="species:ncbi:1280">S. aureus</span>
Gram-positive or Gram-negative bacteria activate human ASMC to release CXCL-8. By contrast Gram-negative bacteria inhibited the release of eotaxin-1 from human ASMCs. E. coli, but not S. aureus induced GMCSF release from cells.
###end p 9
###begin p 10
Our findings that ASMC can respond directly to Gram-negative and Gram-positive bacteria by releasing the neutrophil selective chemokine, CXCL-8, is consistent with what we know about the role of neutrophil recruitment in bacterial infections in the lung. Our findings that bacteria inhibit the release of the eosinophil selective chemokine, eotaxin-1 may help to explain the mechanisms by which bacterial immunotherapy reduces allergic inflammation in the lung.
###end p 10
###begin title 11
Background
###end title 11
###begin p 12
###xml 248 249 248 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 250 251 250 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 274 275 274 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 321 322 321 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 323 324 323 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
In diseases such as asthma, the airway smooth muscle fulfills a contractile role. However, airway smooth muscle cells (ASMC) can also acquire a secretory phenotype with the ability to release inflammatory mediators including cytokines, chemokines [1-4], and lipid hormones [5] when stimulated with cytokines or oxidants [6,7].
###end p 12
###begin p 13
###xml 225 226 225 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 227 228 227 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 484 486 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 645 647 645 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 829 831 829 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 832 834 832 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 979 981 979 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 982 984 982 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1097 1099 1097 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 625 633 <span type="species:ncbi:9606">patients</span>
###xml 756 761 <span type="species:ncbi:9606">Human</span>
###xml 1169 1174 <span type="species:ncbi:9606">human</span>
The role of bacteria in airway inflammation is currently the subject of investigation. For example, bacterial infections may exacerbate asthmatic symptoms and eradication therapy appears to provide some therapeutic benefits [8,9]. On the other hand, low level inoculation immunotherapy with bacterial components may provide therapeutic benefit in the treatment of allergic asthma, presumably by redressing the balance between type1 (Th1; T helper 1) and type 2 inflammatory pathways [10]. In addition to asthma, it has been recognized for some time that bacterial infections are the underlying cause of exacerbations in some patients with COPD [11]. It is therefore important that we understand how bacteria and other pathogens are sensed by airway cells. Human ASMCs express Toll like receptors (TLRs), including TLR2 and TLR4 [12,13]. Stimulation of ASMCs with pathogen associated molecular patterns (PAMPs) including LPS induce either low or undetectable levels of cytokines [12-14], although the sensing of LPS, for example, by ASMCs can be enhanced dramatically by co-culture with monocytes [12]. However the effects of whole bacteria on release of cytokines from human ASMCs has not previously been studied. Moreover, the effect of bacteria or associated PAMPs on the eosinophil- selective chemokines released by airway smooth muscle is not completely understood.
###end p 13
###begin p 14
###xml 54 71 54 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli </italic>
###xml 89 111 89 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 54 70 <span type="species:ncbi:562">Escherichia coli</span>
###xml 89 110 <span type="species:ncbi:1280">Staphylococcus aureus</span>
In the current study we have used whole Gram-negative Escherichia coli and Gram-positive Staphylococcus aureus as model organisms, as well as a range of well characterized PAMPs, to compare directly their effects on the release of CXCL-8, which recruits neutrophils, and eotaxin-1, which recruits eosinophils. The level of GMCSF, which is active on both eosinophils or neutrophils was also measured.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
Materials
###end title 16
###begin p 17
###xml 234 235 234 235 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
Eotaxin-1, CXCL-8 and GMCSF enzyme-linked immunosorbent assays (ELISA) DuoSet kits were purchased from R&D Systems (Abingdon, UK). The cell culture plastic ware was purchased from Falcon Labware (Becton Dickinson, Oxford, UK). The Pam3CSK4, LPS and FSL-1 were purchased from Axxora (UK) Ltd (Nottingham, U.K). All other tissue culture reagents and chemicals were obtained from Sigma (Poole, UK) unless otherwise stated.
###end p 17
###begin title 18
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human airway smooth muscle cell isolation and culture
###end title 18
###begin p 19
###xml 160 161 160 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 378 380 378 380 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 406 408 405 407 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 440 442 438 440 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 494 496 486 488 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 33 41 <span type="species:ncbi:9606">patients</span>
###xml 123 128 <span type="species:ncbi:9606">human</span>
###xml 253 257 <span type="species:ncbi:9913">calf</span>
Main lobar bronchi obtained from patients undergoing lung resection for carcinoma of the bronchus were used for dissecting human ASMC, as previously described [4]. Cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% foetal calf serum FCS supplemented with sodium pyruvate, L-glutamine (2 mM), non-essential amino acids (1:100), penicillin (100 U ml-1)/streptomycin (100 mug ml-1) and amphotericin B (1.5 mug ml-1) in a humidified atmosphere at 37degreesC in air/CO2 (95:5 % vol/vol). Confluent cells were passaged with 0.25% trypsin and 1 mM EDTA. Cells at passages 3-7 from 6 different donors were used in the studies described below. In pilot studies ASMC were initially characterized by positive immunostaining for calponin, smooth muscle alpha-actin and myosin heavy chain. There after they were characterized by their typical morphology and phenotype.
###end p 19
###begin title 20
###xml 15 23 15 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 27 36 27 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 15 22 <span type="species:ncbi:562">E. coli</span>
###xml 27 36 <span type="species:ncbi:1280">S. aureus</span>
Preparation of E. coli and S. aureus
###end title 20
###begin p 21
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 39 49 39 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 69 79 69 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 363 365 357 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g </italic>
###xml 764 766 752 754 <sup xmlns:xlink="http://www.w3.org/1999/xlink">10</sup>
###xml 769 772 757 760 <sup xmlns:xlink="http://www.w3.org/1999/xlink">12 </sup>
###xml 799 801 787 789 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 0 7 <span type="species:ncbi:562">E. coli</span>
###xml 39 48 <span type="species:ncbi:1280">S. aureus</span>
###xml 69 78 <span type="species:ncbi:1280">S. aureus</span>
E. coli, reference strain 0111.B4, and S. aureus H380 were used. The S. aureus H380 was isolated from clinical blood culture and stored frozen in 15% glycerol. This was streaked onto agar plates prior to inoculation of single colonies into RPMI-1640 medium with 10% FCS and glutamine at 37degreesC overnight. The bacteria were pelleted by centrifugation at 800 x g then washed in sterile saline twice. The pellets were re-suspended in sterile saline. In order to quantify the cell density, aliquots of the bacterial suspension were serially diluted and plated onto agar. The bacteria in the bacterial suspensions were killed by heat treatment for 45 min at 80degreesC. The resultant suspensions were plated to confirm the sterility. Suspensions were adjusted to 1010-1012 colony-forming units (CFUml-1) and then frozen with 20% glycerol in aliquots before use in cell culture experiments.
###end p 21
###begin title 22
ELISAs
###end title 22
###begin p 23
Measurement of GMCSF, CXCL-8 and eotaxin-1 in culture supernatants was performed using ELISA DuoSets according to manufactures' instructions (R&D Systems, Abingdon, UK). Supernatants were stored at -80degreesC prior to assay.
###end p 23
###begin title 24
###xml 61 66 <span type="species:ncbi:9606">human</span>
Flow cytometric analysis of TLR2 and TLR4 surface expression human SMC
###end title 24
###begin p 25
###xml 48 50 48 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 299 301 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 185 190 <span type="species:ncbi:9606">human</span>
###xml 211 216 <span type="species:ncbi:9606">human</span>
###xml 342 347 <span type="species:ncbi:9606">human</span>
To determine cell-surface TLR expression, 4 x 104 cells fixed in 3.2% formaldehyde were preincubated in 50 muL of staining buffer (0.5% BSA and 0.1% sodium azide in PBS) containing 10% human serum and 30 mug of human IgG (Sigma) for 30 minutes on ice to block Ig receptors as described previously, [13]. Briefly phycoerythrin-conjugated anti-human TLR2 (clone TL2.1) or TLR4 (clone HTA125), or the relevant phycoerythrin-conjugated isotype control antibodies (IgG2a,kappa or IgG1,kappa; 0.75 mug each; eBioscience, San Diego, Calif) were then added, and the cells were incubated for a further 60 minutes on ice. A FACScan flow cytometer (Becton Dickinson Immunocytometry Systems [BIDS], Oxford, United Kingdom) was used, and typically 10,000 events were acquired in the viable cell region of the forward light scatter/side light scatter plots. Analysis was performed with CELLQuest software (BIDS). The fluorescence signal was calculated as the geometric mean fluorescence intensity of the gated ASMC population.
###end p 25
###begin title 26
Effect of whole bacteria on Eotaxin-1, CXCL-8, and GMCSF release
###end title 26
###begin p 27
###xml 51 53 51 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 61 63 61 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 150 151 150 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 217 219 217 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 243 245 242 244 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 274 276 272 274 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 385 393 383 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 395 396 393 394 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 399 401 397 399 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8 </sup>
###xml 407 409 405 407 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 440 449 438 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 453 454 451 452 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 457 459 455 457 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8 </sup>
###xml 465 467 463 465 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 530 531 522 523 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 185 189 <span type="species:ncbi:9913">calf</span>
###xml 385 392 <span type="species:ncbi:562">E. coli</span>
###xml 440 449 <span type="species:ncbi:1280">S. aureus</span>
Human ASMC were plated at seeding density of 1 x 104 cells/cm2 onto 96 well plates. Confluent cells were cultured in DMEM containing sodium pyruvate [4], L-glutamine (2 mM), 10% foetal calf serum, penicillin (100 U ml-1)/streptomycin (1 mug ml-1), amphotericin B (1,5 mug ml-1). Cells were treated in triplicate with either medium only or a model organism for Gram-negative bacteria, (E. coli 106-108 CFU ml-1), or Gram-positive bacteria, (S. aureus, 106-108 CFU ml-1l), for 24 or 48 hours (h) at 37degreesC in an atmosphere of CO2. The supernatants were collected and stored at -80degreesC to measure the levels of eotaxin-1, CXCL-8, and GMCSF release by using DuoSet ELISA kit (R&D Systems) according to the manufacturers' instructions. The samples were diluted until the cytokine level was within the linear range of the standard curve whenever it was required.
###end p 27
###begin title 28
Effect of selective TLR2 and TLR4 ligands on chemokine release
###end title 28
###begin p 29
###xml 118 120 117 119 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 137 138 136 137 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 176 178 175 177 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 287 289 280 282 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
Confluent cells were treated in triplicate with either medium only or with relevant PAMPs for TLR4 (LPS, 0.01-1 mug ml-1), TLR2/TLR1 (Pam3CSK4), TLR2/TLR6 (FSL-1, 10-1000 ng ml-1), NOD1 (FK565, 10 nM and 100 nM) or NOD2 (MDPLys18, 10 nM and 100 nM) for 24 h or 48 h at 37degreesC in a CO2 incubator.
###end p 29
###begin title 30
Effect of whole bacteria or TLR2/TLR4 ligand on IL-1beta induced chemokine release
###end title 30
###begin p 31
###xml 49 56 49 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 60 61 60 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 64 66 64 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8 </sup>
###xml 72 74 72 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 92 101 92 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 105 106 105 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 109 111 109 111 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8 </sup>
###xml 117 119 117 119 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 140 142 139 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 222 224 218 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 49 56 <span type="species:ncbi:562">E. coli</span>
###xml 92 101 <span type="species:ncbi:1280">S. aureus</span>
Confluent cells were treated with Gram-negative (E. coli, 107-108 CFU ml-1), Gram-positive (S. aureus, 107-108 CFU ml-1), LPS (0.01-1 mug ml-1l) or FK565, 10 nM and 100 nM)I in the presence and absence of IL-1beta (1 ng ml-1) for 24 h before chemokines were measured in the supernatant as described above.
###end p 31
###begin title 32
Effect of selective TLR3 ligand Poly I:C on chemokine release
###end title 32
###begin p 33
###xml 143 151 141 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 154 156 152 154 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 162 164 160 162 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 167 177 165 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 180 182 178 180 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 188 190 186 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 213 216 210 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1 </sup>
###xml 143 150 <span type="species:ncbi:562">E. coli</span>
###xml 167 176 <span type="species:ncbi:1280">S. aureus</span>
Cells were treated in triplicate with either medium only or with Poly I:C (0.01 -10 mug/ml) alone or Poly I:C (1 or mug/ml) in the presence of E. coli (106 CFU ml-1), S. aureus (106 CFU ml-1) or LPS at 0.01 mug ml-1 for 24 h before chemokine release was measured as described earlier.
###end p 33
###begin title 34
Cell number and cell viability
###end title 34
###begin p 35
###xml 251 254 251 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1 </sup>
The cell viability was assessed by the mitochondrial-dependent reduction of MTT to formazan on the remaining cells following all treatments mentioned above. Briefly, following the removal of supernatant, the remaining cells were incubated with 1 mg ml-1 MTT in serum free medium at 37degreesC for 15 min. The MTT was removed and DMSO was added. The OD was read at 550 nm.
###end p 35
###begin title 36
Data and Statistical Analysis
###end title 36
###begin p 37
Data are presented as mean +/- SEM. Data were compared using one-way analysis of variance (ANOVA) followed by Newman-Keuls post-hoc t-test to determine statistical differences after multiple comparisons using Prism software. A probability value of less than 0.05 was considered significant.
###end p 37
###begin title 38
Results
###end title 38
###begin title 39
###xml 24 32 24 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 24 31 <span type="species:ncbi:562">E. coli</span>
Effect of Gram-negative E. coli and associated PAMPs on release of CXCL-8
###end title 39
###begin p 40
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 210 218 210 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 221 223 221 223 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 228 230 228 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8 </sup>
###xml 236 238 236 238 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 316 317 316 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 338 339 338 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 404 406 403 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 452 453 451 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 461 462 460 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 562 563 561 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 0 7 <span type="species:ncbi:562">E. coli</span>
###xml 135 140 <span type="species:ncbi:9606">human</span>
###xml 210 217 <span type="species:ncbi:562">E. coli</span>
###xml 253 258 <span type="species:ncbi:9606">human</span>
###xml 673 678 <span type="species:ncbi:9606">human</span>
E. coli activates PRRs including TLR4 and NOD1. LPS is a PAMP for TLR4 and FK565 is a PAMP for NOD1. Under control culture conditions, human ASMCs released relatively low, but detectable levels of CXCL-8. When E. coli (106 to 108 CFU ml-1) was added to human ASMCs, the release of CXCL-8 was increased at 24 (Figure 1) or 48 hours (table 1). In line with this, cells stimulated with LPS (0.01 to 1 mug ml-1) released increased levels of CXCL-8 (Figure 1; table 1). By contrast, FK565 (10 to 100 nM), did not affect CXCL-8 release when administered alone (Figure 1). In separate experiments, it was noted that FK565 had no interaction with LPS in the release of CXCL-8 from human ASMCs (control, 48.39 +/- 17.9; plus LPS, 161.7 +/- 21.9; plus FK565, 23.07 +/- 8.3 LPS+FK565, 123.9 +/- 17.3, n = 3).
###end p 40
###begin p 41
###xml 0 85 0 85 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of bacteria and associated PAMPs on CXCL-8 release from human ASMCs over 24 h.</bold>
###xml 134 142 134 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bacteria</italic>
###xml 213 214 213 214 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 63 68 <span type="species:ncbi:9606">human</span>
###xml 95 100 <span type="species:ncbi:9606">human</span>
Effect of bacteria and associated PAMPs on CXCL-8 release from human ASMCs over 24 h. Panel A, human ASMCs treated with Gram-negative bacteria, LPS or FK565. Panel B, cells treated with Gram-positive bacteria, Pam3CSK4, FSL-1, MDPLys18. Data represent mean +/- SEM for triplicate of three different donors. * p < 0.05; **p < 0.01; ***p < 0.001 compared with un-stimulated control (medium only).
###end p 41
###begin p 42
###xml 154 161 154 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 166 167 166 167 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 170 172 170 172 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8 </sup>
###xml 178 180 178 180 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 202 204 201 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 77 82 <span type="species:ncbi:9606">human</span>
###xml 154 161 <span type="species:ncbi:562">E. coli</span>
Effect of Gram-negative bacteria and associated PAMPs on CXCL-8 release from human ASMCs over 48 h. ASMCs were treated with either bacteria Gram-negative E. coli, (106-108 CFU ml-1), LPS, (0.01-1 mug ml-1) or FK565, (10 nM and 100 nM). The data represent the mean +/- SEM from triplicate of three different donors.
###end p 42
###begin title 43
###xml 24 34 24 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 24 33 <span type="species:ncbi:1280">S. aureus</span>
###xml 81 86 <span type="species:ncbi:9606">human</span>
Effect of Gram-positive S. aureus and associated PAMPs on release of CXCL-8 from human ASMCs
###end title 43
###begin p 44
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 69 70 69 70 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 153 163 153 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 166 168 166 168 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 173 175 173 175 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8 </sup>
###xml 181 183 181 183 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 249 250 249 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 268 269 268 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 285 286 285 286 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 306 308 306 308 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 336 338 336 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 386 387 386 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 405 406 405 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 447 449 447 449 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 510 511 510 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 0 9 <span type="species:ncbi:1280">S. aureus</span>
###xml 153 162 <span type="species:ncbi:1280">S. aureus</span>
###xml 223 228 <span type="species:ncbi:9606">human</span>
S. aureus activates PRRs including TLR2/TLR1, TLR2/TLR6 and NOD2. Pam3CSK4, FSL-1 and MDPLys18 are PAMPs for TLR2/TLR1, TLR2/TLR6 and NOD2 respectively. S. aureus (106 to 108 CFU ml-1) stimulated the release of CXCL-8 from human ASMCs at 24 (Figure 1) and 48 h (table 1). Similarly Pam3CSK4 (3 to 300 ng ml-1) or FSL-1 (10 to 1000 ng ml-1) increased the release of CXCL-8 at 24 (Figure 1) and 48 h (table 2). By contrast, MDPLys18 (10 to 100 ng ml-1) had no significant effect on the release of CXCL-8 (Figure 1).
###end p 44
###begin p 45
###xml 149 158 149 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 163 164 163 164 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 167 169 167 169 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8 </sup>
###xml 175 177 175 177 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 183 184 183 184 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 203 205 203 205 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 231 233 231 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 77 82 <span type="species:ncbi:9606">human</span>
###xml 149 158 <span type="species:ncbi:1280">S. aureus</span>
Effect of Gram-positive bacteria and associated PAMPs on CXCL-8 release from human ASMCs over 48 h. ASMCs were treated either Gram-positive bacteria S. aureus, (106-108 CFU ml-1), Pam3CSK4 (3 - 300 ng ml-1), FSL-1, (10 - 1000 ng ml-1) or MDPLys18 (10 nM and 100 nM). The data represent the mean +/- SEM of triplicate of three different donors.
###end p 45
###begin title 46
###xml 24 32 24 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 24 31 <span type="species:ncbi:562">E. coli</span>
###xml 82 87 <span type="species:ncbi:9606">human</span>
Effect of Gram-negative E. coli and associated PAMPs on release of eotaxin-1 from human ASMCs
###end title 46
###begin p 47
###xml 106 114 106 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 117 119 117 119 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 124 126 124 126 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8 </sup>
###xml 132 134 132 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 465 473 462 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 597 599 591 593 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8 </sup>
###xml 605 608 599 602 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1 </sup>
###xml 616 617 610 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 106 113 <span type="species:ncbi:562">E. coli</span>
###xml 149 154 <span type="species:ncbi:9606">human</span>
###xml 465 472 <span type="species:ncbi:562">E. coli</span>
Under control culture conditions, ASMCs released relatively low or undetectable levels of eotaxin-1. When E. coli (106 to 108 CFU ml-1) was added to human ASMCs, in experiments from cells of donors where 'basal' levels were detectable, a reduction in 'basal' release was noted (data not shown). In subsequent experiments, cells were stimulated with IL-1beta in order to induce eotaxin-1 release and the effects of co- treatment with bacteria or PAMPs were studied. E. coli induced a concentration dependent reduction in the release of eotaxin-1 stimulated with IL-1beta. This was significant at 108 CFU ml-1 (Figure 2). Neither LPS, nor FK565 given alone or in combination affected the release of eotaxin-1 induced by IL-1beta (data not shown).
###end p 47
###begin p 48
###xml 0 95 0 95 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of Gram-negative or Gram-positive bacteria on eotaxin-1 release in human ASMC over 24 h.</bold>
###xml 120 128 120 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 142 152 142 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 207 209 204 206 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 74 79 <span type="species:ncbi:9606">human</span>
###xml 120 127 <span type="species:ncbi:562">E. coli</span>
###xml 142 151 <span type="species:ncbi:1280">S. aureus</span>
Effect of Gram-negative or Gram-positive bacteria on eotaxin-1 release in human ASMC over 24 h. ASMCs were treated with E. coli (panel A), or S. aureus (panel B) in the present or absent of IL-1beta (1 ng ml-1). Data are mean +/- SEM.; from triplicate of three different donors. * p < 0.05 compared with control (cell stimulated with IL-1beta only).
###end p 48
###begin title 49
###xml 24 34 24 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 24 33 <span type="species:ncbi:1280">S. aureus</span>
###xml 84 89 <span type="species:ncbi:9606">human</span>
Effect of Gram-positive S. aureus and associated PAMPs on release of eotaxin-1 from human ASMCs
###end title 49
###begin p 50
###xml 29 36 29 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 38 48 38 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 51 53 51 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7 </sup>
###xml 59 61 59 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8 </sup>
###xml 67 69 67 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 136 137 136 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 198 208 195 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 305 306 302 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 367 368 364 365 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 29 36 <span type="species:ncbi:562">E. coli</span>
###xml 38 47 <span type="species:ncbi:1280">S. aureus</span>
###xml 116 121 <span type="species:ncbi:9606">human</span>
###xml 198 207 <span type="species:ncbi:1280">S. aureus</span>
###xml 426 431 <span type="species:ncbi:9606">human</span>
Similar to observations with E. coli, S. aureus (107 and 108 CFU ml-1) did not induce the release of eotaxin-1 from human ASMCs (Figure 2). Furthermore, when cells were co-stimulated with IL-1beta, S. aureus tended to reduce eotaxin-1 release, although this did not reach statistical significance (Figure 2). In line with observations from whole bacteria, neither Pam3CSK4 nor FSL-1 nor MDPLys18 affected eotaxin-1 release by human ASMCs (data not shown).
###end p 50
###begin title 51
###xml 24 32 24 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 49 59 49 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 24 31 <span type="species:ncbi:562">E. coli</span>
###xml 49 58 <span type="species:ncbi:1280">S. aureus</span>
###xml 88 93 <span type="species:ncbi:9606">human</span>
Effect of Gram-negative E. coli or Gram-positive S. aureus bacteria on GMCSF release by human ASMCs
###end title 51
###begin p 52
###xml 118 126 118 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 129 131 129 131 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7 </sup>
###xml 137 139 137 139 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8 </sup>
###xml 145 147 145 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 192 193 192 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 205 215 205 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 218 220 218 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7 </sup>
###xml 225 227 225 227 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8 </sup>
###xml 233 235 233 235 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 283 284 283 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 353 361 350 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 365 375 362 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 460 461 454 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 34 39 <span type="species:ncbi:9606">human</span>
###xml 118 125 <span type="species:ncbi:562">E. coli</span>
###xml 205 214 <span type="species:ncbi:1280">S. aureus</span>
###xml 353 360 <span type="species:ncbi:562">E. coli</span>
###xml 365 374 <span type="species:ncbi:1280">S. aureus</span>
Under control culture conditions, human ASMCs released low or undetectable levels of GMCSF. Stimulation of cells with E. coli (107 and 108 CFU ml-1) induced increased release of GMCSF (Figure 3). However, S. aureus (107 or 108 CFU ml-1) had no effect on the release of GMCSF (Figure 3). In the presence of IL-1beta, GMCSF release was increased. Neither E. coli nor S. aureus had any additional effect on GMCSF release in cells stimulated with IL-1beta (Figure 3).
###end p 52
###begin p 53
###xml 0 63 0 63 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of bacteria on GMCSF release from human ASMCs over 24 h.</bold>
###xml 107 114 107 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 153 163 153 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 220 222 217 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1</sup>
###xml 41 46 <span type="species:ncbi:9606">human</span>
###xml 107 114 <span type="species:ncbi:562">E. coli</span>
###xml 153 162 <span type="species:ncbi:1280">S. aureus</span>
Effect of bacteria on GMCSF release from human ASMCs over 24 h. ASMCs treated with Gram-negative bacteria, E. coli, (panel A), or Gram-positive bacteria S. aureus (panel B) in the presence or absence of IL-1beta (1 ng ml-1). The data represent the mean +/- SEM of triplicate of three different donors. ***p < 0.001 compared with un-stimulated control (medium only).
###end p 53
###begin title 54
###xml 43 48 <span type="species:ncbi:9606">human</span>
Effect of Poly I:C on chemokine release by human ASMCs
###end title 54
###begin p 55
###xml 302 310 301 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 313 323 312 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 440 441 439 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 202 207 <span type="species:ncbi:9606">human</span>
###xml 302 309 <span type="species:ncbi:562">E. coli</span>
###xml 313 322 <span type="species:ncbi:1280">S. aureus</span>
Viral PAMPs activate intracellular PRRs. Poly I:C is a synthetic form of viral dsRNA and a selective ligand for TLR3. Poly I:C (0.01 -10 mug/ml) had no effect on the release of CXCL-8 or eotaxin-1 from human ASMCs stimulated for 24 h (data not shown). When cells were co-treated with Poly I:C and LPS, E. coli or S. aureus there was a tendency, which did not reach statistical significance, for eotaxin-1 and CXCL-8 to be increased (Figure 4).
###end p 55
###begin p 56
###xml 0 66 0 66 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of selective Poly I:C on chemokine release from human ASMC.</bold>
###xml 208 215 208 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 244 254 244 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 55 60 <span type="species:ncbi:9606">human</span>
###xml 208 215 <span type="species:ncbi:562">E. coli</span>
###xml 244 253 <span type="species:ncbi:1280">S. aureus</span>
Effect of selective Poly I:C on chemokine release from human ASMC. ASMCs were treated in triplicate for 24 h with either medium only or with TLR3 (Poly I:C) alone or in the present of Gram-negative bacteria, E. coli, or Gram-positive bacteria, S. aureus or LPS (Panels A&B). The data represent the mean +/- SEM of three different donors.
###end p 56
###begin title 57
###xml 31 36 <span type="species:ncbi:9606">human</span>
Expression of TLR2 and TLR4 by human ASMCs
###end title 57
###begin p 58
###xml 29 31 29 31 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 95 96 95 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 230 231 230 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 34 39 <span type="species:ncbi:9606">human</span>
As we have shown previously [13], human ASMCs express detectable levels of TLR2 or TLR4 (Table 3). Incubation of cells with whole Gram-positive or Gram-negative bacteria did not significantly alter levels of TLR expression (Table 3).
###end p 58
###begin p 59
###xml 102 123 102 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. Coli or S. Aureus </italic>
###xml 126 128 126 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8 </sup>
###xml 66 71 <span type="species:ncbi:9606">human</span>
Flow-cytometric analysis of cell surface TLR2 and TLR4 protein in human ASMC. Cells were treated with E. Coli or S. Aureus (108 CFU/ml) for 48 hrs. Data is expressed as ratio of mean fluorescence intensity (MFIr) of cells stained with specific TLR2 or TLR4 antibodies and cells stained with the relevant isotype control antibodies. The data is the mean +/- SEM of n = 3-4 ASMC donors.
###end p 59
###begin title 60
Discussion
###end title 60
###begin p 61
###xml 41 46 <span type="species:ncbi:9606">human</span>
In the current study we demonstrate that human ASMCs respond directly to Gram-negative or Gram-positive bacteria. We also show that there is a differential relationship between the release of CXCL-8 and eotaxin-1 by these cells when stimulated with bacteria.
###end p 61
###begin p 62
###xml 14 22 14 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 39 49 39 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 14 21 <span type="species:ncbi:562">E. coli</span>
###xml 39 48 <span type="species:ncbi:1280">S. aureus</span>
###xml 59 64 <span type="species:ncbi:9606">human</span>
Gram-negative E. coli or Gram-positive S. aureus activated human ASMCs to release CXCL-8. CXCL-8 is a potent chemoatractant for neutrophils. Recruitment of neutrophils is an early event at the site of bacterial infection and these observations identify an innate immune function of ASMCs which may be relevant in conditions such as asthma or COPD.
###end p 62
###begin p 63
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 202 210 202 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 391 393 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 394 396 394 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 568 576 568 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 202 209 <span type="species:ncbi:562">E. coli</span>
###xml 223 228 <span type="species:ncbi:9606">human</span>
###xml 568 575 <span type="species:ncbi:562">E. coli</span>
In most cells, the effects of Gram-negative bacteria can be mimicked by LPS, which activates TLR4 [15]. Gram-negative bacteria also contain peptidoglycan which can activate NOD receptors. The effect of E. coli on CXCL-8 by human airway smooth muscle cells was mimicked by LPS, but not by FK565, which activates NOD1 receptors. In some cell types LPS synergizes with FK565 to activate cells [16,17]. However, in the current study using ASMCs, we found no evidence for interaction between these two pathways. These observations suggest that the ability of Gram-negative E. coli to stimulate airway smooth muscle cells to release CXCL-8 is mediated by TLR4 and not NOD1 receptor activation.
###end p 63
###begin p 64
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 161 162 161 162 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 315 317 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 318 320 318 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 479 489 479 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 479 488 <span type="species:ncbi:1280">S. aureus</span>
Gram-positive bacteria contain PAMPs for TLR2, which can heterodimerize with either TLR1 or TLR6 [18]. In our hands, activation of either the TLR2/TLR1, with Pam3CSK4 or TLR2/TLR6, with FSL-1 resulted in a stimulation of ASMCs and release of CXCL-8. Peptidoglycan from Gram-positive bacteria activates mainly NOD2 [16,19]. MDPLys18 which is a selective ligand for NOD2, had no effect on CXCL-8 release by airway smooth muscle cell; these observations suggest that the effects of S. aureus on airway smooth muscle are mediated by TLR2 and not by NOD receptor activation.
###end p 64
###begin p 65
###xml 65 72 65 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 82 91 82 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 192 200 192 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 246 256 246 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus </italic>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 485 487 485 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 500 502 500 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 503 505 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 65 72 <span type="species:ncbi:562">E. coli</span>
###xml 82 91 <span type="species:ncbi:1280">S. aureus</span>
###xml 127 132 <span type="species:ncbi:9606">human</span>
###xml 192 199 <span type="species:ncbi:562">E. coli</span>
###xml 246 255 <span type="species:ncbi:1280">S. aureus</span>
Interestingly, by contrast to results with CXCL-8, we found that E. coli, but not S. aureus, increased the release of GMCSF by human airway smooth muscle cells. In other cells, the effects of E. coli are mediated principally by TLR4 and those of S. aureus by TLR2 [20]. TLR4 recruits both TRIF/TRAM and MyD88/MAL adapter protein pathways. TLR2, on the other hand, recruits MyD88/MAL only. It may well be, therefore, that CXCL-8 is a MyD88/MAL-dependent gene whereas GMCSF, like M-CSF [21], or NOSII [22,23], is independent of the MyD88 pathway and is mediated by TRIF/TRAM.
###end p 65
###begin p 66
###xml 170 178 167 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 271 280 265 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 326 335 320 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 352 360 346 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 723 725 717 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 790 797 784 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 969 977 963 971 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 1292 1294 1285 1287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1440 1442 1432 1434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 170 177 <span type="species:ncbi:562">E. coli</span>
###xml 271 280 <span type="species:ncbi:1280">S. aureus</span>
###xml 790 797 <span type="species:ncbi:562">E. coli</span>
###xml 969 976 <span type="species:ncbi:562">E. coli</span>
By contrast to results obtained with CXCL-8, we found that bacteria did not stimulate the release of eotaxin-1. In fact, in cells co-treated with IL-1beta, Gram-negative E. coli inhibited eotaxin-1 release. A similar trend was seen for cells stimulated with IL-1beta and S. aureus. If the observations we make here with cells in vitro translate to the in vivo situation, we may expect bacteria to reduce eotaxin-1 in the airways, limit the numbers of eosinophils recruited and reduce the associated respiratory symptoms in allergic airway disease. Interestingly, recent studies have shown that bacterial DNA immunotherapy can successfully inhibit eosinophil recruitment into the airways in models of allergic lung disease [24]. In the current study, we found that the inhibitory effects of E. coli, on eotaxin-1 release were not mimicked by LPS or by FK565 in our experimental conditions. Whilst not tested directly, our observations are consistent with the effects of E. coli on eotaxin-1 release being mediated by DNA and not by TLR4 or NOD receptors. Our data shows that treatment of cells with Poly:IC did not induce CXCL-8 or eotaxin release. We have shown previously that Poly I:C at a concentration of 25 mug/ml induced the release of eotaxin and IL-8 from airway smooth muscle cells [13], but in the current study, we did not find an effect of Poly I:C at 10 mug/ml although eotaxin release has been reported at this concentration [25]. This may be due to the fact that we treated the cells under different conditions, that is, in the presence of serum, while the other studies used serum-free conditions.
###end p 66
###begin p 67
###xml 366 368 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
It is important to note that the observations we report here may well have important implications for other respiratory conditions in which bacterial infections are prevalent such as cystic fibrosis. In cystic fibrosis, colonisation of the lungs with bacteria is known to contribute to exacerbations. Moreover, remodelling of airway smooth muscle in this condition [26-28] may lead to an alteration in the balance of chemokine release in response to bacteria.
###end p 67
###begin title 68
Conclusion
###end title 68
###begin p 69
###xml 68 73 <span type="species:ncbi:9606">human</span>
###xml 347 352 <span type="species:ncbi:9606">human</span>
We show that whole Gram-positive or Gram-negative bacteria activate human airway smooth muscle cells to release CXCL-8. Using selective PAMPs, we establish that the effects of whole bacteria on CXCL-8 are likely to be mediated by TLRs and not by NOD receptors. By contrast to CXCL-8, we found that bacteria inhibited the release of eotaxin-1 from human ASMCs. In the case of eotaxin-1 release, the effects of Gram-negative bacteria did not appear to be mediated by TLR4 or NOD pathways. These observations establish a clear but complex innate immune function of ASMCs with regard to bacterial infections.
###end p 69
###begin title 70
Abbreviations
###end title 70
###begin p 71
###xml 34 41 34 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 43 59 43 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli</italic>
###xml 237 239 231 233 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 255 264 249 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. aureus</italic>
###xml 266 287 260 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus</italic>
###xml 34 41 <span type="species:ncbi:562">E. coli</span>
###xml 43 59 <span type="species:ncbi:562">Escherichia coli</span>
###xml 255 264 <span type="species:ncbi:1280">S. aureus</span>
###xml 266 287 <span type="species:ncbi:1280">Staphylococcus aureus</span>
ASMC: airway smooth muscle cells, E. coli: Escherichia coli, ELISA: Enzyme-linked immunosorbent assays, IL-1beta : Interlukin-1beta, LPS: lipopolysaccharide, MTT: (3- [4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide), PAM3: Pam3 Cys-Ser-(Lys)4, S. aureus, Staphylococcus aureus, TLR: Toll-like receptors
###end p 71
###begin title 72
Competing interests
###end title 72
###begin p 73
The author(s) declare that they have no competing interests.
###end p 73
###begin title 74
Authors' contributions
###end title 74
###begin p 75
RI is the first author to this study and was responsible for the overall collation of the work and had the drive to initiate and complete the study. RI and RS participated in the design and coordination of the study, analyzed the results and helped in drafting the paper. They also contributed to the drafting of the revised manuscript. MS contribution came after the initial review from the journal and included the design, execution and analysis of the experiments showing TLR expression by FACS analysis. MS also contributed to the drafting of the revised manuscript and control data showing that anti-TLR antibodies are unreliable tools for the specific block of responses, this information was included in the response to reviewers. SS provided expert advice and guidance for the overall project, particularly the relevance of this work to the field and was also specifically responsible for all information and concepts relating to the usage of whole bacteria. JAM worked closely with RI at the initial stages and throughout the course of this study. JAM, together with RI, was responsible for the initial draft of the manuscript and design of the basic study. KFC conceived of the study in general terms with JAM and RI. KFC participated in its design and coordination, helped with interpretation of data and the drafting of the manuscript. All authors have read and approved the manuscript.
###end p 75
###begin title 76
Acknowledgements
###end title 76
###begin p 77
This work was supported by a Program Grant, from the Wellcome Trust (KFC), the British Heart Foundation (JAM) and an unconditional educational award from E. Lilly (JAM).
###end p 77
###begin article-title 78
Airway smooth muscle cells: contributing to and regulating airway mucosal inflammation?
###end article-title 78
###begin article-title 79
###xml 62 67 <span type="species:ncbi:9606">human</span>
Regulation of TNF-alpha-induced eotaxin release from cultured human airway smooth muscle cells by beta2-agonists and corticosteroids
###end article-title 79
###begin article-title 80
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human airway smooth muscle cells secrete vascular endothelial growth factor: up-regulation by bradykinin via a protein kinase C and prostanoid-dependent mechanism
###end article-title 80
###begin article-title 81
Regulation of airway smooth muscle cell immunomodulatory function: role in asthma
###end article-title 81
###begin article-title 82
###xml 89 94 <span type="species:ncbi:9606">human</span>
Role of cyclo-oxygenase-2 induction in interleukin-1beta induced attenuation of cultured human airway smooth muscle cell cyclic AMP generation in response to isoprenaline
###end article-title 82
###begin article-title 83
###xml 74 79 <span type="species:ncbi:9606">human</span>
TGF-beta 1 stimulates IL-8 release, COX-2 expression, and PGE2 release in human airway smooth muscle cells
###end article-title 83
###begin article-title 84
Cigarette smoke induces IL-8, but inhibits eotaxin and RANTES release from airway smooth muscle
###end article-title 84
###begin article-title 85
Respiratory infections and asthma: current treatment strategies
###end article-title 85
###begin article-title 86
Advances in basic and clinical immunology
###end article-title 86
###begin article-title 87
Biologic therapies for the treatment of asthma
###end article-title 87
###begin article-title 88
The role of bacteria in airway inflammation in exacerbations of chronic obstructive pulmonary disease
###end article-title 88
###begin article-title 89
Agonists of Toll-like Receptors 2 and 4 Activate Airway Smooth Muscle via Mononuclear Leukocytes
###end article-title 89
###begin article-title 90
###xml 58 63 <span type="species:ncbi:9606">human</span>
Toll-like receptor 2, 3, and 4 expression and function in human airway smooth muscle
###end article-title 90
###begin article-title 91
Cooperative molecular and cellular networks regulate Toll-like receptor-dependent inflammatory responses
###end article-title 91
###begin article-title 92
Toll-like Receptor-4 Mediates Lipopolysaccharide-induced Signal Transduction
###end article-title 92
###begin article-title 93
Regulatory regions and critical residues of NOD2 involved in muramyl dipeptide recognition
###end article-title 93
###begin article-title 94
###xml 81 86 <span type="species:ncbi:9606">Human</span>
Synergistic Effect of Nod1 and Nod2 Agonists with Toll-Like Receptor Agonists on Human Dendritic Cells To Generate Interleukin-12 and T Helper Type 1 Cells
###end article-title 94
###begin article-title 95
Saturated Fatty Acid Activates but Polyunsaturated Fatty Acid Inhibits Toll-like Receptor 2 Dimerized with Toll-like Receptor 6 or 1
###end article-title 95
###begin article-title 96
NOD-LRR proteins: role in host-microbial interactions and inflammatory disease
###end article-title 96
###begin article-title 97
Toll-Like Receptor 4, But Not Toll-Like Receptor 2, Is a Signaling Receptor for Escherichia and Salmonella Lipopolysaccharides
###end article-title 97
###begin article-title 98
Cutting Edge: Recognition of Gram-Positive Bacterial Cell Wall Components by the Innate Immune System Occurs Via Toll-Like Receptor 2
###end article-title 98
###begin article-title 99
TLRs: Differential Adapter Utilization by Toll-Like Receptors Mediates TLR-Specific Patterns of Gene Expression
###end article-title 99
###begin article-title 100
Differential effects of Gram-positive versus Gram-negative bacteria on NOSII and TNF[alpha] in macrophages: role of TLRs in synergy between the two
###end article-title 100
###begin article-title 101
###xml 156 190 <span type="species:ncbi:11246">bovine respiratory syncytial virus</span>
Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccine
###end article-title 101
###begin article-title 102
###xml 60 65 <span type="species:ncbi:9606">human</span>
TLR3-mediated synthesis and release of eotaxin-1/CCL11 from human bronchial smooth muscle cells stimulated with double-stranded RNA
###end article-title 102
###begin article-title 103
Structural changes to airway smooth muscle in cystic fibrosis
###end article-title 103
###begin article-title 104
Muscling into cystic fibrosis airways
###end article-title 104
###begin article-title 105
###xml 68 73 <span type="species:ncbi:9606">human</span>
Macrolides inhibit IL-17 induced IL8 and 8-isoprostane release from human airway smooth muscle cells
###end article-title 105

